Visit Nanotechnology Characterization Laboratory (NCL) was founded by the National Cancer Institute (NCI) in 2004, in collaboration with the FDA and NISTas part of a public-private partnership aimed at advancing the science required for the future.e to accelerate the development of promising nanotechnology-based therapies and diagnostics.

NCL, part of the Frederick National Laboratory for Cancer Research (FNLCR), tested more than 500 unique nanomaterials submitted by over 125 researchers from all over the world.

NCL has just published its annual report 2023which highlights advances in research and trends in applications, including :

• The NCL test cascade (submission and application trends)
• Protocols and new technologies
• Nanotechnology formulation
• Publication of validated and recognized harmonized characterization methods

NCL launches a call for applications for several cutting-edge technologies:

• Lipid nanoparticles (LNP)
• Nucleic acid-based therapeutic nanotechnologies
• Imaging agents
• Immunotherapies

International requests for NCL services represent 19% of the total number of requests received, and the dossiers submitted have an acceptance rate of 48%.

If you're developing any of these technologies, NCL is interested in hearing from you!

Visit our website https://www.cancer.gov/nano/research/ncl/about-0  for more information